Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 10, Pages 2163-2171
Publisher
American Society of Hematology
Online
2020-05-21
DOI
10.1182/bloodadvances.2020001508
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
- (2019) Isabel G. Amsler et al. LEUKEMIA & LYMPHOMA
- Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
- (2019) John R. Jones et al. HAEMATOLOGICA
- Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study
- (2019) Theresa E. Hahn et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Imaging and Bone Marrow Assessments Improve Minimal Residual Disease Prediction in Multiple Myeloma
- (2019) Rafael Alonso et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma
- (2019) Laura Rosiñol et al. BLOOD
- Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA
- (2019) Herve Avet-Loiseau et al. Clinical Lymphoma Myeloma & Leukemia
- Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
- (2018) Chiara Cerrato et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
- (2018) Rafat Abonour et al. ANNALS OF HEMATOLOGY
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
- (2018) Robert M. Rifkin et al. CLINICAL THERAPEUTICS
- Maintenance Treatment and Survival in Patients With Myeloma
- (2018) Francesca Gay et al. JAMA Oncology
- Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
- (2018) Manuela Gambella et al. CANCER
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- (2018) L. Rasche et al. LEUKEMIA
- Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
- (2017) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
- (2017) R Chakraborty et al. LEUKEMIA
- Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
- (2017) J Martinez-Lopez et al. LEUKEMIA
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma
- (2016) Idrees Mian et al. CANCER
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
- (2016) J R Jones et al. Blood Cancer Journal
- Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
- (2016) Stefania Oliva et al. Oncotarget
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
- (2011) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started